tiprankstipranks
Harrow reports Q4 core EPS 40c, consensus 13c
PremiumThe FlyHarrow reports Q4 core EPS 40c, consensus 13c
5d ago
CMS approves Harrow’s pass-through application for corticosteroid TRIESENCE
Premium
The Fly
CMS approves Harrow’s pass-through application for corticosteroid TRIESENCE
8d ago
Harrow Health: Strong Financial Performance and Strategic Initiatives Drive Buy Rating with 40% Revenue Growth Outlook
Premium
Ratings
Harrow Health: Strong Financial Performance and Strategic Initiatives Drive Buy Rating with 40% Revenue Growth Outlook
14d ago
Harrow sees Q4 revenue $65M-$67M, consensus $58.4M
PremiumThe FlyHarrow sees Q4 revenue $65M-$67M, consensus $58.4M
15d ago
Harrow sees FY24 revenue $198M-$200M, consensus $191.2M
Premium
The Fly
Harrow sees FY24 revenue $198M-$200M, consensus $191.2M
15d ago
Harrow Health options imply 17.9% move in share price post-earnings
Premium
The Fly
Harrow Health options imply 17.9% move in share price post-earnings
15d ago
Harrow initiated with a Buy at H.C. Wainwright
PremiumThe FlyHarrow initiated with a Buy at H.C. Wainwright
2M ago
Harrow price target lowered to $58 from $65 at Craig-Hallum
Premium
The Fly
Harrow price target lowered to $58 from $65 at Craig-Hallum
2M ago
Harrow announces  Amir Shojaei, PharmD, PhD joins as CSO
Premium
The Fly
Harrow announces Amir Shojaei, PharmD, PhD joins as CSO
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100